Related by context. All words. (Click for frequent words.) 67 Prostate Lung Colorectal 66 Screening Trial 66 Prostate Cancer Prevention 66 Ovarian PLCO Cancer 64 Intervention Trial GAIT 63 number NCT# ClinicalTrials.gov 63 PLCO 62 ENESTnd 62 Carotid Revascularization Endarterectomy vs. 62 BCIRG 61 ACRIN 61 ELCAP 61 Gynecologic Oncology Group 61 Prostate AdenoCarcinoma Treatment 61 AIM HIGH 61 Ovarian Cancer Screening 60 Trial NLST 60 ExTRACT TIMI 60 malignant mesothelioma Alfacell 60 Clinical Antipsychotic Trials 60 Digital Mammographic Imaging 60 multicenter randomized clinical 60 LibiGel Phase III 60 CHAMPION PCI 60 prospective observational cohort 60 Celecoxib APC trial 60 EURIDIS 60 ONTARGET 60 ThermoDox ® clinical 59 Pre RELAX AHF 59 Oral Fingolimod 59 LUX Lung 59 PCPT 59 Dialysis Outcomes 59 Screening Trial DMIST 59 Phase 1b clinical trials 59 RE LY 59 CALGB # [001] 59 APPRAISE 59 AVOREN 59 Alpha Tocopherol Beta Carotene 59 STRIDE PD 59 Randomized Phase II 59 NO# [002] 59 HCV SPRINT 58 CALGB 58 PRESEPT 58 European Randomized Study 58 ongoing Phase IIIb 58 Phase Ib II 58 SPIRIT FIRST 58 Sorafenib HCC Assessment 58 LungAlert TM 58 Stenting Trial CREST 58 Evaluation Program CTEP 58 BRIM3 58 HORIZONS AMI trial 58 NCCTG 58 AVADO 58 Truvada tablets 58 HGPIN 58 Phase 1a clinical 58 ID NCT# 58 Multicenter AIDS 58 Prospective Randomized 58 evaluating mipomersen 58 Topline Results 58 RE LY ® 58 Combination REOLYSIN R 58 Phase Ib clinical 58 CALERIE 58 SIMPADICO 58 PROTECT AF 57 International Verapamil SR 57 NSABP B 57 CLARITY TIMI 57 AIR2 Trial 57 BARI 2D 57 By JENNIFER LEARN 57 metastatic castration resistant 57 Trandolapril 57 HCV RESPOND 2 57 MAGE A3 ASCI 57 Quinamed 57 Randomized Double blind 57 Cholesterol Levels SPARCL 57 MEND CABG 57 CT Colonography Trial 57 PSMA ADC 57 novel VDA molecule 57 CARE HF 57 evaluating tivozanib 57 CARDIA study 57 NABTT 57 PRE SURGE 57 deCODE ProstateCancer TM 57 ABCSG 57 blinded randomized placebo controlled 57 PERSEUS clinical program 57 See CLINICAL PHARMACOLOGY 57 Advanced Renal Cell 57 evaluating Actimmune 57 INSPIRE Trial Phase III 57 Lipid Lowering Treatment 57 Deforolimus 57 RECORD1 57 PCI ExTRACT TIMI 57 Cancer Incidence Mortality 57 Aggressive Reduction 57 Wisconsin Sleep Cohort 57 Randomized Phase 57 interferon gamma 1b 57 Lung Cancer Trial 57 ORAL Solo 57 CAMMS# 57 HPTN 57 Asthma Intervention 57 Phase Ib Clinical Trial 57 Non Melanoma Skin 57 CURRENT OASIS 7 57 Multicenter Phase 57 PANVAC VF 57 Genasense ® oblimersen 56 axitinib 56 Multicentre 56 THAT ARE DIFFICULT TO 56 prospective multicentre 56 EXPLORE Xa 56 confirmatory clinical 56 Framingham Offspring Study 56 CTAP# Capsules 56 selenium supplementation 56 HDAC Inhibitor 56 Medullary Thyroid Cancer 56 BRAF mutated 56 Lp PLA 2 56 Advaxis Phase 56 TO AVOID PREGNANCY WHILE 56 bazedoxifene conjugated estrogens 56 TRA 2P 56 ANCHOR trial 56 ALSYMPCA 56 Adjuvant Chemotherapy 56 By ERIC HJERSTEDT 56 Phase IIIb clinical 56 Inflammatory Markers 56 ECASS 56 endometriosis ovarian cysts 56 TMC# C# 56 Xelox 56 KRAS variant 56 mg BID dose 56 Bayer HealthCare Onyx Pharmaceuticals 56 GISSI 56 multicenter placebo controlled 56 PROactive Study 56 PROLARIS 56 Computed Tomographic 56 CHARISMA trial 56 neratinib 56 ASTEROID 56 oral ridaforolimus 56 trastuzumab emtansine T DM1 56 CYP#A# CYP#D# 56 Phase III ThermoDox 56 Breast Density 56 atrasentan 56 Group RTOG 56 journal Gynecologic Oncology 56 SUCCEED trial 56 European Sepsis Trial 56 Antitumor Activity 56 Phase 2b Clinical Trial 56 iPrEx 56 dutasteride 56 phase IIIb 56 Lymphocytic 56 Randomized Evaluation 56 GAMMAGARD 56 II Clinical Trial 56 HYVET 56 Swedish Mammography Cohort 56 mertansine 56 First Patient Enrolled 56 REGARDS 56 Investigator Initiated 56 Common Toxicity Criteria 56 CombAT 56 NCCTG N# 56 Glucosamine chondroitin Arthritis 56 Randomized Controlled Trials 56 Lancet Oncology journal 56 BOLDER II 55 Adenoma Prevention 55 pertuzumab 55 cobiprostone 55 Hormone Refractory Prostate Cancer 55 Abbott Trilipix 55 Nicotine Vaccine 55 MGd 55 Chicago Multidisciplinary Symposium 55 Patient Accrual 55 Glucosamine Chondroitin Arthritis 55 ToGA 55 Ocrelizumab 55 brivanib 55 Renal Cell Carcinoma RCC 55 #rd Annual CTRC 55 Phase #b/#a clinical 55 Non Alcoholic Steatohepatitis 55 DAPT Study 55 KIF6 carriers 55 Preclinical Study 55 Intervention Effectiveness CATIE 55 HPV-#/# 55 multicenter randomized controlled 55 LAB CGRP 55 Geochimica et Cosmochimica Acta 55 CAPACITY trials 55 TIMI Study Group 55 ACUITY trial 55 Dose Escalation 55 Platelet Inhibition 55 CIMZIA ™ 55 COPERNICUS 55 NGFN 55 NSABP 55 www.cancerconsultants.com 55 longitudinal observational study 55 viral kinetic 55 Telik logo TELINTRA 55 REVIVE Diabetes 55 multicentre randomized 55 Tumor Response 55 TG MV 55 randomized Phase III 55 Common Terminology Criteria 55 MERLIN TIMI 55 ACCORD Lipid 55 pharmacokinetic PK 55 NCI Cancer 55 Cardiotoxicity 55 Immune Tolerance Network 55 TRO# 55 ASCO GU 55 BMC Musculoskeletal Disorders 55 Intervention Effectiveness 55 forodesine 55 substudy 55 www.pranabio.com 55 Rasilez Tekturna 55 Aortic Stenosis 55 ACCOMPLISH 55 APEX PD 55 Pediatric Oncology Branch 55 APEX AMI trial 55 ErbB2 positive 55 relapsed MM 55 SCD HeFT 55 Tesmilifene 55 EchoCRT 55 iPrEx study 55 HMG CoA reductase inhibitors 55 adenoma recurrence 55 APTIVUS 55 Vaccine Adjuvant 55 ADMIRE HF 55 randomized controlled Phase 55 Ann Oncol 55 Severe Sepsis 55 Group NCCTG 55 subanalysis 55 COU AA 55 azathioprine monotherapy 55 adjuvant endocrine therapy 55 ARBITER 6 55 R# #mg BID 55 REACH Registry 55 placebo controlled Phase III 55 Diabetes ACCORD 55 CALGB # [002] 55 Val HeFT 55 Neanderthal Genome Project 55 Randomized Study 54 http:/www.reprosrx.com 54 oral deforolimus 54 ARCALYST ® rilonacept 54 Hormone Receptor Positive 54 prospective observational studies 54 Prednisone Against Refractory 54 J Clin Endocrinol Metab 54 Colposcopy 54 Phase III Clinical Trial 54 Immunotherapeutic 54 Clinical Outcome 54 MADIT II 54 Intervention Trial 54 Clinical Trials Update 54 Hepatotoxicity 54 metastatic HRPC 54 Pharmacokinetic parameters 54 Phase 2b Study 54 ENGAGE AF TIMI 54 PROactive study 54 CAPRIE 54 Stenting Trial 54 Lung Cancer Screening 54 Exelixis XL# 54 Ranolazine 54 Pooled Analysis 54 ADVANCE ILLUMINATE 54 CYT# potent vascular disrupting 54 ZACTIMA 54 PREVAIL 54 Prostate Cancer Patients 54 MADIT 54 Heart Failure Trial 54 Sipuleucel T 54 multicenter phase 54 recurrent metastatic ovarian cancer 54 HuMax EGFr 54 Randomized Controlled 54 ENDEAVOR IV 54 Raloxifene STAR 54 Adjuvant Treatment 54 prostate cancer CaP 54 DIRECT Trial 54 EUS FNA 54 Environ Health Perspect 54 chemoprevention trials 54 ug dose 54 Genetic Markers 54 DMIST 54 PRoFESS 54 Prolongs Survival 54 ARRY # 54 Molecular Cancer 54 PREZISTA r arm 54 non nucleoside HCV 54 Gastric Cancer 54 NCIC CTG 54 www.cellgenesys.com 54 CIN2 + 54 Biological Therapy 54 EGFR HER2 54 PATENT FOR 54 Cohort Study MACS 54 riociguat 54 Survivorship Program 54 YOUR LOCAL ANIMAL SHELTER 54 metastatic pancreatic 54 Carotid Endarterectomy 54 AVERROES 54 PET FROM 54 CTRC AACR San Antonio 54 Kaplan Meier analysis 54 GLOBOCAN 54 multicenter trials 54 Hsp# Inhibitor 54 Group B CALGB 54 elotuzumab 54 Edge STudy 54 Phase IIIb study 54 Randomized trials 54 evaluating carfilzomib 54 Multiple Ascending Dose 54 Research Network EDRN 54 CLL8 54 BENICAR HCT 54 Aggressive Prostate Cancer 54 Menopausal hormone therapy 54 azilsartan medoxomil 54 tesmilifene 54 olaparib 54 Phase III AFFIRM 54 IIa clinical 54 #-# Full Text 54 Hematological 54 Randomized Trials 54 Phase III Clinical Trials 54 Radiation Therapy Oncology 54 ongoing Phase 1b 54 Clinical Outcomes Utilizing Revascularization 54 Trastuzumab DM1 54 Neoadjuvant Chemotherapy 54 phase IIb study 54 EORTC 54 Study Evaluating 54 PRIMO CABG2 54 REALITY Trial 54 Abiraterone Acetate 54 lexidronam injection 54 Uterine Cancer 54 Randomized Clinical Trial 54 MOTIVATE 54 Phase 1b trial 54 advanced adenoma 54 Synta Announces 54 ISEL 54 Biomarker Study 54 oral FTY# 54 recurrent metastatic 54 Mg Usa 54 Phase III metastatic melanoma 54 enzastaurin 54 Arch Intern Med 54 Proc Am Soc 54 www.ilgenetics.com 54 Acta Scandinavica 54 Tumor Sequencing Project 54 BRIM2 54 ICON7 54 Clinical Practice Guideline 54 Rakai Uganda 54 AIR CF1 54 Invasive Breast Cancer 54 Depression Study TADS 54 please visit www.advaxis.com 54 Shows Promise Against 53 phase IIa clinical 53 Prostate Cancer Risk 53 Arch Surg 53 registrational Phase 53 LUMINATE 53 Antiviral Activity 53 Women Ischemia Syndrome 53 K ras mutations 53 Zemplar Capsules 53 DF HCC 53 Gynecological Cancer 53 recurrent glioblastoma multiforme 53 Multi Ethnic Study 53 ACTEMRA TM 53 Abstract Accepted 53 Phase IIb III 53 pivotal bioequivalence 53 GW# [003] 53 Intravenous CP 53 EVEREST II 53 ALN HPN 53 Nasdaq PPHM 53 SABCS 53 specific CCR9 antagonist 53 Multicenter Randomized 53 ALLHAT 53 Phase Ib IIa 53 vidofludimus 53 BZA CE 53 sunitinib malate 53 faulty BRCA2 gene 53 Hepatitis C Infection 53 Adenomas 53 morphometric vertebral fractures 53 ANNOUNCES PARTNERSHIP WITH 53 multicenter Phase 53 phase IIb trial 53 VITAL Trial 53 Stent Thrombosis 53 Prostate Cancer Outcomes 53 prospective observational 53 Enzastaurin 53 HORIZONS AMI 53 Clinical Trial Results 53 metachronous 53 MET amplification 53 MADIT CRT 53 www.syntapharma.com 53 MD Moross Institute 53 phase IIb 53 XL# SAR# 53 elevated LDL cholesterol 53 Hepatocellular Carcinoma HCC 53 ADVANCE PD 53 Thrombolysis 53 Genes Predict 53 2 inhibitor CYT# 53 hormone receptor negative 53 GOUT 53 Phase #/#a trial 53 VICTOR E1 53 RenalGuard System TM 53 CCX# 53 basal bolus regimen 53 prostate carcinogenesis 53 Tanespimycin 53 pan HDAC inhibitor 53 refractory chronic lymphocytic 53 Postdoctoral Position 53 STRATEGY FOR AN OPEN 53 FAME Study 53 non nucleoside inhibitor 53 kidney urologic 53 Venous Thromboembolism 53 Acta Psychiatrica Scandinavica 53 Metastatic Renal Cell Carcinoma 53 PROMACTA CARES 53 Acute Ischemic Stroke 53 Phase 2a trial 53 http:/www.cticseattle.com 53 randomized Phase 2b 53 brivaracetam 53 CATIE AD 53 fluvastatin 53 INTERHEART study 53 Randomized Phase III 53 bepotastine besilate nasal spray 53 Cardiac Allograft Rejection 53 ASCO GI 53 multicenter clinical 53 THE STUDY 53 OPT CHF 53 Anti Tumor Activity 53 Completes Patient Enrollment 53 Phase Ib study 53 e# [005] 53 BLOOM Behavioral modification 53 Autologous Stem Cell Transplantation 53 pharmacodynamic effects 53 immatics 53 Prospective Multicenter 53 Neoadjuvant 53 WEB OF SCIENCE 53 antiretroviral naïve 53 Brentuximab Vedotin SGN 53 CLIRS trial 53 prospectively defined 53 hyperphenylalaninemia HPA due 53 depsipeptide 53 PROSTVAC TM 53 ANNOUNCES ANNUAL 53 #F FDG PET 53 Sentinel node biopsy 53 multicenter randomized Phase III 53 www.immuneregen.com 53 Pharmacokinetic PK 53 GYTS 53 Coronary Artery Calcium 53 Phase III VISTA 53 Lars Sjostrom 53 essential thrombocythemia ET 53 CERVARIX 53 Non inferiority 53 Afatinib 53 dapagliflozin plus 53 ERSPC 53 MEK Inhibitor 53 Levels Linked 53 Unstable Angina 53 CARDIA 53 Vidofludimus 53 Left Ventricular Dysfunction 53 PROSTVAC VF 53 Am J Pathol 53 HGS ETR2 53 Controlled Trial 53 multicentre randomized controlled 53 Celebrex celecoxib 53 identifier NCT# 53 RTOG 53 NATRECOR R 53 J Virol 53 Phase 2a Trial 53 VADT 53 Protease Inhibitor 53 Successfully Completes Phase 53 SYMMETRY trial 53 Preclinical Models 53 B vitamin supplementation 53 bone metastasis 53 MIST II 53 DNA methyltransferase inhibitors 53 fosbretabulin 53 SHEDS LIGHT ON 53 Folfox 53 TransVax ™ 53 multicenter prospective 53 Study ADCS 53 Decompensated Heart Failure 53 phase IIb clinical 53 IMC #B 53 Degarelix 53 Obes Res 53 RECIST Response Evaluation Criteria 53 National Surgical Adjuvant 53 renal cell carcinomas 53 worsening thrombocytopenia 53 Meta Analysis 53 JAMA. 53 MADIT CRT trial 53 YONDELIS 53 AAG geldanamycin analog 53 subgroup analyzes 52 AML MDS 52 Dr. Pingpank 52 Denufosol 52 Diamyd r 52 ENDEAVOR III 52 landmark ATHENA 52 dose escalation Phase 52 Epidermal Growth Factor Receptor 52 HCV NS5B polymerase 52 Demonstrates Efficacy 52 #:#-# [020] 52 cathepsin K inhibitor 52 Serious Adverse Events 52 asymptomatic metastatic 52 arzoxifene 52 INITIATE 52 Ann Rheum Dis 52 Dose Ranging Study 52 Pivotal Trial 52 Randomized Clinical Trials 52 Arch Neurol 52 Nymox NX 52 TEMSO 52 FOLOTYN ® 52 beta carotene supplementation 52 #:# -# [004] 52 STUDIES AND 52 Nonalcoholic Fatty Liver Disease 52 Investigational Drug 52 Advanced Melanoma 52 RE MODEL 52 PLCO trial 52 J Rheumatol 52 R roscovitine 52 Placebo Controlled Trial 52 Molecular Genetic 52 assessing T DM1 52 TAXUS IV 52 Cancer Epidemiol Biomarkers Prev 52 placebo controlled clinical 52 vismodegib 52 MYTHOS trial 52 pexelizumab trials 52 Intelligence Network NCIN 52 EMPHASIS HF trial 52 Dose Response 52 NCT# ClinicalTrials.gov 52 Randomized controlled 52 Group NCIC CTG 52 multicenter Phase III 52 Health Initiative Observational 52 Myocardial Infarction TIMI Study 52 AACR San Antonio 52 Vivancos File 52 Aplidin R 52 Azedra 52 Novel Oral 52 Atherosclerosis MESA 52 galiximab 52 AACR IASLC Joint 52 chromium supplementation 52 journal Transfusion 52 Multicenter 52 Prenatal Alcohol 52 eprotirome 52 Angiolix 52 Patient Registry 52 Tyrima 52 TITLE Auctions 52 double blinded randomized 52 PRTX 52 Nephrol Dial Transplant 52 ritonavir boosted 52 Clinical Trial Evaluating 52 Ixempra 52 designated HVTN 52 Meta analyzes 52 Insulin Resistance Atherosclerosis 52 estrogen progestin therapy 52 Gad Getz 52 Hedgehog Pathway Inhibitor 52 prospective randomized placebo 52 R rosiglitazone maleate 52 Initiate Phase 52 ABSORB clinical 52 undergone radical prostatectomy 52 CTA# Injection 52 SPIRIT IV 52 ACCLAIM 52 stage IIIb IV 52 J Am Coll 52 sorafenib Nexavar 52 J Antimicrob Chemother 52 Arimidex Tamoxifen Alone 52 Motesanib 52 Pivotal Phase 52 Study AREDS 52 mITT population 52 ACTIVE W 52 Halozyme Ultrafast Insulin 52 Nuvelo Announces 52 Preclinical Data 52 Metastatic Prostate Cancer 52 Shows Efficacy 52 Late Breaker 52 PROSTVAC ® 52 Cervical Dysplasia 52 placebo controlled Phase 52 ONTARGET R 52 CHD CVD 52 PHASE III 52 PUBLISHED IN 52 MEND CABG II 52 www.osteologix.com 52 Blinatumomab 52 R#/MEM # 52 LymphoStat B belimumab 52 targeting miR 52 underwent surgical resection 52 Delcath Phase III 52 secondary efficacy endpoint 52 IMPACT IMmunotherapy 52 cardio renal 52 Atherosclerosis Risk 52 Castration Resistant Prostate Cancer 52 Genitourinary Cancers Symposium 52 treatment naive genotype 52 FASEB J. 52 intravesical infusion therapy 52 androgen suppression 52 J Clin Oncol 52 Serevent salmeterol 52 IMPROVE IT 52 avosentan 52 Endocrine Practice 52 Ceplene/IL-2 52 CT Colonography 52 PERSEUS 52 Severe Asthma 52 OPTIMIZE 52 Therapeutic Efficacy 52 SPORE grant 52 recurrent glioma 52 Glioma 52 dependent kinase inhibitor 52 dose escalation clinical 52 CAPRISA 52 severe oral mucositis 52 Clostridium difficile Infection 52 Curaxin CBLC# 52 p# biomarker 52 Traumatic Spinal Cord Injury 52 quadrivalent HPV vaccine 52 lintuzumab 52 Fondaparinux 52 Response Evaluation Criteria 52 clinical pharmacology studies 52 talabostat 52 grade cervical intraepithelial 52 Statin Drugs 52 CEQ# 52 Advanced Neuroendocrine Tumors 52 BioNumerik 52 Drug Shows Promise 52 Malignant Melanoma 52 AVN# Phase 52 ENDEAVOR clinical 52 HDL Cholesterol 52 Genome Sequencing Centers 52 sUA 52 BR.# 52 http:/www.ncbi.nlm.nih.gov/pubmed/# 52 preclinical efficacy 52 Double Blind Placebo 52 homocysteine concentrations 52 www.malbex.ca 52 Phase IIa trials 52 Medidur TM FA 52 www.resverlogix.com 52 teriflunomide 52 ELACYT 52 investigational protease inhibitor 52 HIV HCV coinfected 52 PRECiSE 52 Lancet Neurology journal 52 Primary endpoints 52 Polyp Prevention Trial 52 Phase 1b Clinical Trial 52 VTEU 52 DLTs 52 Baltimore Longitudinal Study 52 Western Airborne Contaminants 52 HuLuc# 52 standard chemotherapy regimen 52 phase Ib 52 www.arqule.com 52 oral antidiabetic medication 52 ATACAND 52 observational cohort 52 Pyridorin TM 52 Drug Prevents 52 PRESENTED AT 52 solithromycin 52 Confirmatory Phase 52 Osteoporotic Fractures 52 anastrazole 52 Subgroup analysis 52 mapatumumab 52 www.novartis.com 52 BRCA2 mutation carriers 52 Bowel Project NSABP 52 Oncotype DX ® 52 Multicenter Automatic Defibrillator Implantation 52 Islet Transplantation 52 Dietary Modification Trial 52 REMINYL ® 52 Combination Treatment 52 PROVE IT 52 A2 Lp PLA2 52 Demonstrates Significant 52 ovarian endometrial 52 ANN INTERN MED 52 LHRH antagonists 52 tramiprosate Alzhemed TM 52 Ocular Hypertension Treatment 52 Anthrax Toxin 52 Wactawski Wende 52 EQUIP OB 52 Phase IIb Trial 52 randomized discontinuation trial 52 Antigen Specific 52 TAXUS VI 52 Am J Epidemiol 52 ABSORB trial 52 Phase III randomized 52 HCV Protease Inhibitor 52 Phase III multicenter 52 ARIXTRA 52 PROVENGE ® 52 www.geovax.com 52 Ozarelix 51 ONCOLOGY 51 Framingham Offspring 51 IN PATIENTS WITH 51 NCIC Clinical Trials 51 TRITON TIMI 51 phase IIa 51 SW3d #,#-# Tex. Crim 51 Predict Risk 51 PFO migraine 51 Therapeutic Targets 51 metastatic GIST 51 Platinol ® cisplatin 51 www.helicosbio.com 51 Pivotal Clinical Trial 51 abiraterone acetate 51 LENALIDOMIDE 51 Spine Patient Outcomes 51 doi #.#/fj.#-# 51 Metastatic Melanoma 51 ORACLE MS 51 Heart Failure Therapies 51 ACCORD Eye 51 ThermoDox R 51 Teriflunomide 51 Daclizumab 51 Cloretazine ® 51 cervical carcinoma 51 ARCOXIA 51 Squamous 51 EOquin TM phase 51 #:#-#,# [003] 51 tarenflurbil 51 ULORIC 51 Vertebral Fracture 51 candesartan 51 WHO TOOK 51 sunitinib Sutent 51 Randomized Double Blind Placebo 51 EBUS FNA 51 Health Initiative WHI 51 Patient Enrollment 51 Phase IIIb 51 Faslodex 51 neoadjuvant treatment 51 Colorectal Screening 51 farletuzumab 51 Clinical Trial Data 51 Tarceva TM 51 Aflibercept 51 Diamyd Medical Diamyd 51 cisplatin gemcitabine 51 ASSERT 51 histologically confirmed 51 Nonalcoholic Steatohepatitis 51 randomized multicentre 51 sorafenib tablets 51 prostate ovarian 51 deforolimus 51 HER2 amplified 51 Outpatient Setting 51 EMBO Molecular Medicine 51 prospective multicenter 51 Bucindolol 51 mg administered orally 51 #:#-# [033] 51 Colorectal Cancers 51 Subgroup Analysis 51 neoadjuvant 51 Phase 2b Trial 51 ELOXATIN 51 HPV# 51 Cloretazine 51 MDACC 51 Complications Trial 51 Scandinavian Simvastatin Survival 51 ERATO 51 mTOR mammalian target 51 Biodesix 51 Adjuvant chemotherapy 51 LEXIVA r 51 blind multicenter 51 Darapladib 51 Coronary Revascularization 51 tubulin inhibitor 51 TASKi2 51 Study ARIC 51 Phase 2b monotherapy 51 cilostazol 51 WHEL 51 SPL# Gel vaginal microbicide 51 Onrigin 51 colorectal bowel 51 www.adeonapharma.com 51 AIR CF2 51 TNFerade TM 51 cat dander allergy 51 CLARITY study 51 FROM THE OPINIONJOURNAL 51 Netherlands Cohort Study 51 RE LY trial 51 Dasatinib 51 Patient Enrolment 51 Chronic Liver Disease 51 Psychiatry Clin Neurosci 51 NELS 51 sunitinib Sutent ® 51 Refractory Angina 51 Skin sterol 51 www.criticaloutcome.com 51 Presents Preclinical 51 Leukemias 51 drug conjugate 51 Heart Transplant Recipients 51 Phase III Pivotal 51 #:#-# [024] 51 KRAS gene mutations 51 irbesartan 51 Breast Cancer Recurrence 51 multicenter multinational 51 IMPROVE HF 51 Allogeneic 51 http:/www.celgene.com 51 Complicated Skin 51 Communities ARIC study 51 Initiated Phase 51 colorectal carcinoma 51 VESTASYNC 51 trastuzumab DM1 T DM1 51 refractory metastatic 51 RG# ITMN 51 registrational trial 51 Trial Evaluating 51 Therapy Evaluation 51 rosuvastatin Crestor 51 multicenter randomized double 51 ICAAC IDSA 51 NPC 1C 51 PF # [002] 51 journal Biomacromolecules 51 Cerebrovascular Diseases 51 goserelin 51 Clinical Oncology JCO 51 Wintergreen Resort STAY 51 Follicular Lymphoma 51 SORT OUT 51 Crit Rev 51 #:#-# [032] 51 XL# anticancer compounds 51 Ambulatory Blood Pressure 51 randomized controlled multicenter 51 cervical intraepithelial neoplasia 51 Kidney Int 51 Optical Coherence Tomography 51 www.cticseattle.com 51 retrospective cohort study 51 FDA APPROVES 51 cisplatin vinorelbine 51 Observational Study 51 TACI Ig 51 AVAiL 51 www.cougarbiotechnology.com 51 Cardiac Resynchronization 51 advanced adenomas 51 dysglycemia 51 Nord Trøndelag Health 51 CIMZIA TM certolizumab pegol